Literature DB >> 7944309

Replication of human papillomaviruses in cell culture.

M A Stanley1.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 7944309     DOI： 10.1016/0166-3542(94)90047-7

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


× No keyword cloud information.
  7 in total

1.  The inhibitory activity of the AU-rich RNA element in the human papillomavirus type 1 late 3' untranslated region correlates with its affinity for the elav-like HuR protein.

Authors:  M Sokolowski; H Furneaux; S Schwartz
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

Review 2.  Topical imiquimod: a review of its use in genital warts.

Authors:  C M Perry; H M Lamb
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

3.  mRNA instability elements in the human papillomavirus type 16 L2 coding region.

Authors:  M Sokolowski; W Tan; M Jellne; S Schwartz
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

4.  Viral trans-factor independent replication of human papillomavirus genomes.

Authors:  Daraporn Pittayakhajonwut; Peter C Angeletti
Journal:  Virol J       Date:  2010-06-10       Impact factor: 4.099

5.  Oxidative stress in patients with nongenital warts.

Authors:  Sezai Sasmaz; Ozer Arican; Ergul Belge Kurutas
Journal:  Mediators Inflamm       Date:  2005-08-31       Impact factor: 4.711

6.  Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18.

Authors:  Kelly L Smith; Amanda Tristram; Kathleen M Gallagher; Alison N Fiander; Stephen Man
Journal:  Int Immunol       Date:  2004-12-27       Impact factor: 4.823

Review 7.  Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response.

Authors:  Alfredo Amador-Molina; José Fernando Hernández-Valencia; Edmundo Lamoyi; Adriana Contreras-Paredes; Marcela Lizano
Journal:  Viruses       Date:  2013-10-28       Impact factor: 5.048
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.